Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 86   

Articles published

ARNA 1.50 -0.07 (-4.46%)
price chart
Arena Pharmaceuticals, Inc. (ARNA) Stock Rating Upgraded by Zacks Investment ...
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, ARN reports.
Boehringer Ingelheim, Arena Pharmaceuticals to research schizophrenia drug ...  Healio
Biotech Stock under consideration today: Arena Pharmaceuticals, Inc  iStreetWire
Arena Pharmaceuticals, Inc. (ARNA) Upgraded to Buy at Zacks Investment Research
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, AnalystRatings.
Technical Analysis: Arena Pharmaceuticals, Inc.  CWRU Observer
Arena Pharmaceuticals, Inc. (ARNA) Stock Rating Lowered by Zacks Investment ...  Corvus Business Newswire
Arena Pharmaceuticals Incorporated (NASDAQ:ARNA) Short Interest Increased By 7.13%
Arena Pharmaceuticals, Inc. is a biopharmaceutical firm focused on discovering, developing and commercializing drugs that target G protein-coupled receptors .
Short Interest in Arena Pharmaceuticals, Inc. (ARNA) Declines By 22.6%
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw a large decrease in short interest in December.
Zacks Investment Research Downgrades Arena Pharmaceuticals, Inc. (ARNA) to Hold  Corvus Business Newswire
Arena Pharmaceuticals, Inc. (ARNA) Upgraded by Zacks Investment Research to Buy  Zolmax
Company Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Drops by -11.18%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has lost 11.18% during the past week and dropped 20.53% in the last 4 weeks.
Buzzing Stock : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?  Vanguard Tribune
Can Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) hit $5?
As per Zacks, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock holds a bullish price target of $5. The brokerages listed in Zacks poll have collectively set a price target of $3.75 on firm's stock.
Arena Pharmaceuticals Inc. (ARNA) Drops 9.69% on January 19
Arena Pharmaceuticals Inc. (ARNA) was one of the Russell 2000's biggest losers for Tuesday January 19 as the stock slid 9.69% to $1.49, a loss of $-0.1599 per share.
Arena - Belviq Sales Continue Negative Trend
The weight loss sector seems to be demonstrating that the "newness" of branded anti-obesity pills is wearing off, and the pill that is feeling the biggest pinch in Belviq from Arena Pharmaceuticals (NASDAQ:ARNA). Traditionally, the beginning of a new ...
Traders Round Up: Arena Pharmaceuticals, Inc. (ARNA), Lannett Company, Inc. (LCI)
The company's RSI reading has hit 47.14. The stock edged higher by 11.03% to close previous trading session at USD 1.61.
Arena- Belviq Sales Start Off 2016 Slowly
Arena Pharmaceuticals (NASDAQ:ARNA) is in a much different situation this year in terms of the prospects for Belviq than they were a year ago.